ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report

OBJECTIVE: The mechanism by which evinacumab, a fully human monoclonal antibody directed against ANGPTL3 (angiopoietin-like 3 protein) lowers plasma LDL (low-density lipoprotein) cholesterol levels in patients with homozygous familial hypercholesterolemia is unknown. We investigated apoB (apolipopro...

Descripción completa

Detalles Bibliográficos
Autores principales: Reeskamp, Laurens F., Millar, John S., Wu, Liya, Jansen, Hans, van Harskamp, Dewi, Schierbeek, Henk, Gipe, Daniel A., Rader, Daniel J., Dallinga-Thie, Geesje M., Hovingh, G. Kees, Cuchel, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Translational Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057526/
https://www.ncbi.nlm.nih.gov/pubmed/33691480
http://dx.doi.org/10.1161/ATVBAHA.120.315204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057526/
https://www.ncbi.nlm.nih.gov/pubmed/33691480
http://dx.doi.org/10.1161/ATVBAHA.120.315204

Ejemplares similares